Headquartered in Madrid, Veos Pharmaceuticals operates at the intersection of human health, agriculture, and environmental systems — translating research into products that perform in the real world.
Veos Pharmaceuticals, S.L. was founded to commercialize biotechnology breakthroughs across three platforms: human health, agriculture, and environmental systems. Each platform is built on validated science, defensible intellectual property, and a clear path to market.
From our Madrid headquarters, we operate as a fully integrated company — owning research, formulation, regulatory filings, and direct-to-market distribution across Europe and North America.
We have been profitable since 2024 and continue to expand our portfolio through internal R&D, strategic partnerships, and selective in-licensing of clinically validated assets.
Every product traces back to peer-reviewed research, validated mechanisms, and a measurable endpoint. No marketing claim outruns the data.
Profitable since 2024. We invest in opportunities with clear unit economics, defensible IP, and identifiable buyers — not science-fair projects.
From molecule to marketplace. Owning the chain compresses time-to-market and protects margin from end to end.
Patients, growers, and communities — not investor decks. Our scorecard is the outcomes we deliver in the field, on the shelf, and at the bedside.
Spanish and EU manufacturing partnerships ensure regulatory compliance, supply continuity, and quality control we directly oversee.
We collaborate with universities, distributors, and growers who share our standards — and we walk away from deals that don't meet them.
Established to commercialize biotechnology breakthroughs across pharmaceutical, nutraceutical, agricultural, and environmental platforms.
First commercial launches across human health and nutraceuticals, establishing direct-to-consumer presence in Canada and the EU.
The company reached operating profitability — funded entirely by founders and revenue, without dilutive capital.
Field trials initiated across multiple crop systems; environmental water-treatment platform advanced toward commercial pilot.
Strategic partnership extends clinical-grade ophthalmic care across Spain, France, Germany, and Italy.